American Society of Hirudotherapy

H. nipponia / H. tianjinensis Monomeric Decorsins

Monomeric and oligomeric decorsins + hirudins + hirudin-like factors across H. nipponia and H. tianjinensis — Kalatehjari 2026 recombinant platelet-aggregation characterization.

Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Monomeric and oligomeric decorsins + hirudins + hirudin-like factors across H. nipponia and H. tianjinensis — Kalatehjari 2026 recombinant platelet-aggregation characterization.
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

H. nipponia / H. tianjinensis monomeric decorsin antiplatelet activity in vitro does NOT establish clinical efficacy. No FDA-approved derivative; neither species is on the FDA K040187 cleared device species list.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Source species
Hirudo nipponia + Hirudo tianjinensis
Discovered
2026 · Kalatehjari P et al.
H. nipponia / H. tianjinensis Monomeric Decorsins molecular structure

Biological Targets

  • platelet GPIIb/IIIa receptor; thrombin (paralogous hirudins)

Key Citations

  1. Kalatehjari P et al. (2026), Parasitol Res · PMID 41653280

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.